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Objectives The goal of this study was to assess the associations between renal artery calcification (RAC) and mortality in a
healthy outpatient cohort with no known cardiovascular disease (CVD).
Background Studies in individuals with known diabetes and kidney disease have suggested that RAC confers additional mor-
tality risk independent of coronary artery calcification, but this hypothesis has not been explored in healthier
populations.
Methods RAC was assessed by using computed tomography scan in healthy outpatients with no known CVD. Cox propor-
tional hazards models were used to examine the association of RAC with mortality.
Results The mean age of participants was 57 years; 42.6% were women. RAC was present in 622 (14%) of 4,450 partic-
ipants. Over a median follow-up of 8.2 years, there were 178 deaths. After adjustment for age, sex, diabetes,
smoking, cholesterol, and family history of CVD, the presence of RAC conferred a 60% increased hazard for
all-cause mortality (hazard ratio [HR]: 1.63 [95% confidence interval (CI): 1.17 to 2.29]). Adjustment for calcifi-
cation in other vascular beds attenuated this association (HR: 1.40 [95% CI: 0.99 to 1.97]). Adjustment for hy-
pertension, a potential mediator of the association, did not substantially change the results (HR: 1.44 [95% CI:
1.02 to 2.03]). Adding RAC to a model including Framingham risk and coronary artery calcification improved the
predictive ability of the model, from 0.73 to 0.77 (p  0.0002); the net reclassification index was 14.4% for the
addition of RAC. Results for cardiovascular mortality were not significant and were limited by the small number
of cardiovascular deaths.
Conclusions RAC was associated with an increased risk of subsequent all-cause mortality in healthy outpatient individuals,
independent of traditional cardiac risk factors. The risk was modestly attenuated by adjustment for vascular cal-
cification in other vascular beds, suggesting partial confounding by systemic calcified atherosclerosis. The effect
did not seem to be mediated by hypertension. (J Am Coll Cardiol 2012;60:1079–85) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.015Among those without clinically apparent cardiovascular
disease (CVD), coronary artery calcification (CAC), a
marker of subclinical CVD, has been established as a risk
factor for incident cardiovascular events and mortality (1,2).
An increased prevalence of renal arterial disease, including
stenosis and calcification, has been noted in persons with
coronary artery disease and systemic vascular disease (3,4).
Calcification of the renal arteries has also been reported in
studies of individuals with overt renovascular disease (5).
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accepted June 7, 2012.Despite these known relationships, the association of calci-
fication in the renal vasculature with mortality has not been
described. Thus, it is unclear if renal artery calcification
(RAC) is simply a marker of systemic vascular calcium
burden or whether it provides independent risk information.
There are reasons to believe that RAC may be an
independent risk factor for mortality. RAC is linked with
calcification in other vascular beds (6) but is less common
than coronary calcification in population-based studies. Its
presence may thus suggest a different and possibly more
severe vascular calcification phenotype. The presence of
RAC may also be a marker of atherosclerosis-mediated
hypertension with activation of the renin-angiotensin sys-
tem (7). In support of this link, RAC has been associated, in
asymptomatic individuals, with prevalent hypertension in-
dependent of the presence or severity of calcification in
other vascular beds (8). In addition, RAC may be related to
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well-documented associations with
cardiovascular disease and mor-
tality (9). In select populations
with diabetes and proteinuric
kidney disease, the presence of
RAC has been associated with
more rapid progression of kidney
disease and with mortality (10).
To our knowledge, however, no
previous study has evaluated the
link between RAC and mortality
in the general population.
Using data from a large cohort
of adults without CVD who un-
derwent whole-body computed tomography (CT) scans
primarily for cardiac risk assessment, the relation between
RAC and all-cause mortality was investigated. We hypoth-
esized that RAC would be associated with mortality, inde-
pendent of traditional cardiovascular risk factors, and that
this association would be independent of systemic calcifica-
tion. Given the association between RAC and hypertension,
we hypothesized that hypertension would at least partially
mediate this association.
Methods
Subjects. This study comprised a cohort of community-
welling individuals (N  4,950) who were seen for
preventive medicine services, including whole-body CT
scanning, at a university-affiliated center in La Jolla, Cali-
fornia, between 1999 and 2003. This cohort has been
described in detail previously (8,11). In brief, this was a
population in which subjects either self-referred or were
referred on the recommendation of their personal physician
as an adjunct to their standard preventive health care. The
majority of these individuals (99%) had no known coronary
disease at the time of the visit. The visit included an
assessment of standard cardiac risk factors and whole-body
CT scans extending from the carotid arteries to the sym-
physis pubis. Coronary calcium was scored at the time of the
preventive visit and reported to the subject. Calcification in
other vascular beds was scored for research purposes after
the visit had taken place.
All subjects completed a detailed health history, including
self-reported medication use for hypertension, diabetes, or
high cholesterol, and had serum lipid and glucose measure-
ments obtained by finger stick using the Cholestech LDX
system (Alere, Inc., Waltham, Massachusetts). Participants
were included regardless of whether they were fasting at the
time of the laboratory tests. Excluded were individuals with
a history of CVD (myocardial infarction, stroke, transient
ischemic attack, angina, or coronary revascularization; n 
45); subjects whose scans did not allow scoring of renal
Abbreviations
and Acronyms
CAC  coronary artery
calcification
CHD  congenital heart
disease
CT  computed
tomography
CVD  cardiovascular
disease
NRI  net reclassification
index
RAC  renal artery
calcificationartery calcium data (n  452); and subjects for whom vital astatus could not be determined (n  3). A total of 4,450
ndividuals were included in the final analysis.
Because the study involved de-identified, existing data, a
aiver of informed consent was granted by the University of
alifornia, San Diego, institutional review board, which
pproved the study.
Clinical, laboratory, and history measures. Blood pres-
ure was measured in the right upper extremity after the
ubject had rested in the seated position for 5 min. Hyper-
ension was defined as systolic blood pressure 140 mm Hg,
iastolic blood pressure 90 mm Hg, and/or reported use
f antihypertensive medication. Diabetes mellitus was de-
ned by current use of antiglycemic medications or a casual
lucose level 200 mg/dl. Individuals with a total:high-
ensity lipoprotein cholesterol ratio 5 and/or those who
eported the use of a medication to treat high cholesterol
evels were classified as dyslipidemic. Family history of
ongenital heart disease (CHD) was defined as a CHD
vent before age 55 years in a first-degree relative. Smoking
tatus was classified as current, former, or never.
maging. An Imatron C-150 scanner (GE Medical Sys-
ems, Milwaukee, Wisconsin) was used to obtain CT scans
rom the base of the skull to the pubic symphysis. All images
ere obtained during a single session using 100-ms scan
ime and proceeded caudally from the base of the skull to
he symphysis pubis. Each bed was obtained by a distinct
can of the segment in question using the following slice
hicknesses: 3 mm for the coronary bed; 6 mm through the
eck, abdomen, and pelvis; and 5 mm for the thorax.
easurements of calcified atherosclerosis were obtained in
he following vascular beds: coronary, carotid, thoracic
orta, abdominal aorta, renal, and iliac arteries. The coro-
ary and carotid images were analyzed at the time of the CT
can; other vascular beds were analyzed retrospectively.
alcium scoring in the different vascular beds was per-
ormed by using the method described by Agatston et al.
12). Calcium in the renal arteries was categorized as arising
rom the ostium or within the renal arterial segment on each
ide. The sum of the right and left ostial and arterial
egments of the renal arteries were used to calculate an RAC
core. Similar sums were used to calculate calcium burden in
he other vascular beds. The number of vascular beds other
han the renal arteries with calcium present was then
abulated. The reader for renal artery calcium only viewed
mages that contained the renal arteries; this individual was
linded to the scores for the other beds.
ortality outcomes. All-cause mortality was determined
hrough August 31, 2009, by using Social Security Death
ndex searches to determine mortality status for all individ-
als in the cohort. Date and cause of death were obtained
rom death certificate information.
tatistical analysis. To examine demographic associations
ith the presence of RAC, this variable was dichotomized
ased on presence (score 0) or absence (score of zero) of
ny RAC. Differences in the distributions of baseline
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September 18, 2012:1079–85 Renal Artery Calcification and Mortalitycharacteristics between those with and without RAC were
described using t or chi-square tests, as appropriate.
To examine the effects of the burden of RAC, we further
divided those with non-zero RAC scores into quintiles. For
graphical modeling, we compared each of these quintiles of
RAC versus the group with no RAC. In addition, multi-
variate models were examined by using the continuous RAC
score among those with RAC; because the distribution of
RAC scores was highly skewed, this score was log-
transformed for mortality analyses, setting the log-score of
those without calcium to zero.
Kaplan-Meier curves were examined to visually inspect
the mortality rates of those with and without RAC. Subse-
quently, Cox proportional hazards models were constructed
to examine the adjusted association between RAC and
all-cause and cardiovascular mortality. Initial models were
adjusted for age and sex. A second model was adjusted for
most traditional risk factors (former or current smoking,
dyslipidemia, diabetes, and family history of CVD). A third
model adjusted for the CAC score (modeled as log[CAC
1]). We then adjusted for atherosclerosis in other vascular
beds (carotid, thoracic and abdominal aorta, and iliac
arteries), using the number of other beds affected divided by
the number of other beds with scorable calcium (e.g.,
percentage of other beds affected) as an adjustment variable.
We tested for heterogeneity in the association of RAC on
mortality according to age and sex.
We postulated that the association between RAC and
mortality might be mediated by hypertension, because
hypertension can be caused by atherosclerotic renovascular
disease and because hypertension itself is then a risk factor
for mortality. Thus, we examined whether hypertension
mediated the association between RAC and mortality.
Nested models were developed, first without and then with
adjustment for hypertension; we then examined the change
in the hazard ratios (HRs) of RAC.
HRs and 95% confidence intervals (CIs) were calculated
for each estimate. We also tested for proportionality of
hazards by visual examination of log(log) survival curves.
All of the p values were 2 tailed, with a p value 0.05
onsidered to indicate statistical significance.
Last, receiver-operating characteristic curves were devel-
ped for prediction of all-cause mortality and cardiovascular
ortality. Because the study outcome of interest was mor-
ality rather than cardiovascular events, the base model
ncluded the calculated Framingham hard CHD score
ecause this best approximates mortality rather than event-
ased risk (13,14); risk cutoffs of 5%, 5% to 15%, and
15% were chosen for the low, intermediate, and high
roups, respectively, because standard predefined thresholds
ave not been established for all-cause mortality. Additional
odels added CAC, RAC, or both (modeled as log-
CAC1] and log[RAC1]) to the base model. We
dditionally calculated the integrated discrimination index
nd net reclassification index (NRI) (15) for adding CAC,
cRAC, and both to these models and tested whether these
improvements were statistically significant.
All of the statistical analyses were conducted by using SAS
version 4.3 (SAS Institute, Inc., Cary, North Carolina).
Results
Of the 4,450 study subjects, 622 (14%) had RAC. These
individuals were older (mean age 68.8 vs. 54.8 years) and
more likely to have diabetes, hyperlipidemia, and a history
of smoking than those without RAC (Table 1). Individuals
with RAC were also more likely to have systolic hyperten-
sion and to have calcification in other vascular beds; those
with RAC had on average 4.3 other vascular beds with
calcification present, whereas those without RAC had 1.9
other vascular beds with calcification present (6,8).
In total, 178 deaths (41 were cardiovascular related)
occurred over a median 8.2 years of follow-up; univariate
associations between variables of interest and mortality are
shown in Table 2. Those with greater burden of RAC had
lower survival rates (log-rank p value for trend 0.01) (Fig. 1).
mong those without RAC, the age-adjusted mortality rate was
.3 per 1,000 person-years (95% CI: 1.88 to 3.02), and among
Participant CharacteristicsAccording to Absence/Presence of RACTable 1 Parti ipant Chara teristicsAccording to Absence/Presence of RAC
Characteristic
No RAC
(n  3,828)
RAC Present
(n  622) p Value
Age (yrs) 54.8 10.3 68.8 8.7 0.0001
Female 1,656 (43.2) 243 (39.1) 0.05
Total cholesterol (mg/dl) 208.2 42.0 202.6 39.4 0.004
HDL (mg/dl) 53.2 17.3 51.7 16.7 0.052
LDL (mg/dl) 122.1 36.9 116.8 35.7 0.002
Systolic BP (mm Hg) 124.3 16.5 131.4 16.0 0.0001
Diastolic BP (mm Hg) 78.1 (10.3) 78.2 10.4 0.79
Renal artery calcium
score
0 44 (17–115)
No. of other vascular
beds with calcium
1.9 1.7 4.3 1.06 0.001
CAC score (Agaston
units)
1.03 (0–62.40) 218 (17.02–769.20) 0.001
Smoker 0.001
Current 360 (9.4) 63 (10.1)
Former 1,229 (32.1) 310 (49.8)
Never 2,239 (58.4) 249 (40.0)
Family history of CHD 915 (23.9) 162 (26.0) 0.25
Diabetes 70 (1.8) 16 (2.6) 0.21
Hypertension 1,160 (30.3) 316 (50.8) 0.0001
Medication use for
hypertension
526 (13.7) 201(32.3) 0.0001
Medication use for
hyperlipidemia
461 (12.0) 130 (20.9) 0.0001
BMI (kg/m2) 27.1 5.1 26.9 4.1 0.21
Framingham CHD risk
score
5 (2–12) 12 (6–20) 0.001
Deceased 96 (2.5) 82 (13.2) 0.0001
Values are mean  SD, n (%), or median (interquartile range). p value for t test (continuous) or
chi-square test (categorical) as appropriate.
BMI  body mass index; BP  blood pressure; CAC  coronary artery calcification; CHD 
ongenital heart disease; HDL  high-density lipoprotein; LDL  low-density lipoprotein; RAC 
renal artery calcification.
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Renal Artery Calcification and Mortality September 18, 2012:1079–85those with RAC, the age-adjusted mortality rate was 4.24 per
1,000 person-years (95% CI: 2.97 to 6.07). There was a significant
trend toward increasing age-adjusted mortality rates with increas-
ing quintiles of RAC (p  0.001) (Fig. 2).
In models adjusted for age and sex, the presence of RAC
was associated with a 76% higher risk of death (Table 3).
After further adjustment for demographic and cardiac risk
factors, the presence of RAC still conferred a 60%
increase in mortality risk and remained associated with a
nearly 40% increase in risk (HR: 1.40 [95% CI: 0.99 to
1.97]) after adjustment for vascular calcification in other
locations.
In age- and sex-adjusted proportional hazards models,
each log-increase in RAC score among the 622 participants
with any RAC present conferred a modest increase in the
hazard of mortality (HR: 1.18 [95% CI: 0.98 to 1.4]).
Additional adjustment for cardiovascular risk factors and
Univariate Hazard Ratios of MortalityTable 2 Univariate Hazard Ratios of Mortality
Variable
Univariate Hazard of
Mortality (95% CI)
Age (per year) 1.11 (1.10–1.13)
Male 0.98 (0.73–1.32)
Diabetes mellitus 2.47 (1.22–5.00)
Hypertension (presence) 2.17 (1.62–2.91)
Hyperlipidemia (presence) 0.99 (0.73–1.35)
Current smoking 1.65 (1.09–2.50)
Family history of CVD 1.09 (0.78–1.50)
BMI (per kg/m2) 0.99 (0.96–1.02)
Coronary artery calcification (presence) 3.60 (2.44–5.25)
BMI  body mass index; CI  confidence interval; CVD  cardiovascular disease.
Figure 1 Kaplan-Meier Curves for
Mortality at Different Levels of RAC
Mortality curves over time for those with no renal artery calcification (RAC) and
increasing levels of RAC as follows: 0  no RAC; quintile (Q) 1, 1 to 13 Agat-
ston units (AU); Q2, 14 to 29 AU; Q3, 30 to 66 AU; Q4, 67 to 133 AU;
Q5, 134 to 779 AU. The log-rank p test for trend was 0.01.number of other calcified beds further attenuated this
association (HR: 1.14 [95% CI: 0.94 to 1.38]).
When the possible mediating effect of hypertension was
evaluated, we found little attenuation of mortality risk by
hypertension, regardless of whether hypertension was added
before or after addition of other adjustment variables. For
example, adjusting for hypertension after adjustment for
other traditional risk factors (after model 2) (Table 3)
changed the HR associated with the presence of RAC
minimally from 1.63 (95% CI: 1.17 to 2.29) to 1.66 (95%
CI: 1.18 to 2.34); adding hypertension at the end of the
modeling process had a similar minimal effect on the hazard
associated with the presence of RAC. The receiver-
operating characteristic models (Fig. 3) adding CAC and
RAC to a predictive model, including the hard FRS,
demonstrated improvement in the C-statistic, integrated
discrimination index, and NRI with sequential addition of
CAC and RAC (Table 4). Adding RAC to a model
including hard Framingham risk score and CAC generated
an improvement in the C-statistic from 0.73 to 0.77 (p 
.0002). The NRI for the model including RAC compared
ith that including Framingham risk score and CAC was
4.4% (p for comparison  0.002).
A set of parallel models were conducted for cardiovascular
ortality. There were 41 confirmed cardiovascular deaths
vailable for analysis. Table 3 shows Cox proportional
azards regression models, which demonstrate attenuation
f the risk for cardiovascular mortality with relatively wide
onfidence limits after addition of successive adjustment
ariables. Similarly, Table 4 displays the C-statistic values,
integrated discrimination index, and NRI analyses for car-
Figure 2 Age-Adjusted Rates of
All-Cause Mortality at Different Levels of RAC
Yearly mortality rates per 1,000 person-years, adjusted for age, corresponding
to the categories of renal artery calcification (RAC) as in Figure 1.diovascular mortality; although the addition of RAC to
a adjustm
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not reach statistical significance.
Discussion
RAC was a relatively common occurrence in this cohort of
asymptomatic adults, affecting 14%, and was associated with
a substantial increase in mortality risk even after adjustment
for demographic and traditional cardiovascular risk factors.
RAC was more prevalent in those with vascular calcification
in other beds, and adjustment for the presence of other
vascular calcification and hypertension attenuated but did
not eliminate the association between RAC and mortality.
Despite this adjustment, individuals with RAC remained at
approximately 50% greater mortality risk.
We considered whether hypertension was a potential
mediator of the remaining association between RAC and
mortality. In these analyses, hypertension had a trivial effect
on the association regardless of when it was added to the
models, suggesting that the association between RAC and
mortality was independent of hypertension. Previous angio-
Hazard of All-Cause Mortality and Cardiovascular Mortality at DiffeTable 3 Hazard of All-Cause Mortality and Cardiovascular Mort
Age and Sex Adjusted Risk Adjus
All cause mortality (272 deaths)
RAC (yes/no) 1.76 (1.26–2.45) 1.63 (1.17–
Cardiovascular mortality (41 deaths)
RAC (yes/no) 1.42 (0.73–2.78) 1.23 (0.61–
Values are hazard ratio (95% confidence interval) *Adjusted for smoking, hypercholesterolemia, dia
djusted for percentage of other beds with vascular calcification. §Fully adjusted, with additional
Abbreviations as in Table 1.
Figure 3 ROC Curves for Prediction of
All-Cause Mortality by Using FRS, CAC, and RAC
Area under the receiver-operating characteristic (ROC) curves for Framingham
risk score (FRS) alone: 0.69; for FRS plus coronary artery calcification (CAC):
0.73; for FRS, CAC, and renal artery calcification (RAC) together: 0.77.
p values for comparisons between ROC statistics: all 0.01.graphic studies have demonstrated that RAC is not strongly
associated with overt, flow-limiting renal arterial disease
(15). Our data support the hypothesis that the independent
effect of RAC on mortality is not entirely explained by
decreased blood flow to the kidney and corresponding
increases in blood pressure as mediated by the renin-
angiotensin system, but is instead part of a systemic vascular
calcification phenotype in which vascular calcification and
hypertension may be parallel processes.
In previous studies, RAC was strongly associated with
calcification in other vascular beds in those with diabetes
(16), in those with overt renovascular disease (17), and in
those without clinical CVD (6). These findings suggest that
RAC is likely part of a systemic process and contributes to
mortality risk perhaps by marking the severity of the
atherosclerotic disease burden.
We are aware of 1 small study examining RAC and
mortality, which evaluated a cohort of 172 individuals with
diabetes and kidney disease (10). In that study, RAC had
significant associations with a combined outcome of end-
stage renal disease and mortality even after adjustment for
CAC. The study participants did not have measures of
calcification in vascular beds other than the coronary and
renal beds, and the prevalence of both RAC and CAC were
substantially higher than in our study (31% and 74%,
respectively). That study reported only a combined end
point, with most events being progression to end-stage renal
disease, and separate analyses of mortality outcomes were
not presented. Our study extends the finding of an inde-
pendent association of RAC with mortality to a healthy,
outpatient population with a relatively low prevalence of
RAC and to nondiabetic individuals.
Our findings should be interpreted in the context of
existing data regarding noncoronary vascular calcification.
Although previous studies have shown that CAC is associ-
ated with both cardiovascular and all-cause mortality
(19,20), findings for noncoronary calcium have not been
entirely consistent and seem to depend on the vascular bed
and outcome studied. Thoracic calcification, for example,
has been associated with total mortality and CVD events
(21,22); abdominal aortic calcification has been linked to
CVD and CVD-related mortality (23). Although our find-
ings were suggestive of a stronger association between renal
artery calcification and all-cause mortality rather than car-
evels of RACat Different Levels of RAC
CAC Adjusted† Fully Adjusted‡ Putative Mediator Adjusted§
1.49 (1.06–2.11) 1.40 (0.99–1.97) 1.44 (1.02– 2.03)
1.05 (0.52–2.10) 0.95 (0.48–1.88) 1.01 (0.50– 2.01)
and family history of cardiovascular disease. †Additionally adjusted for log(CAC 1). ‡Additionally
ent for presence of hypertension.rent Lality
ted*
2.29)
2.44)
betes,diovascular mortality, the number of cardiovascular deaths
cation
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seen in this study therefore does not eliminate the possibility
of an association with CVD mortality. It is also possible that
the presence of RAC makes individuals more hemodynam-
ically fragile and less likely to survive noncardiac illnesses,
thus explaining the substantially higher all-cause mortality
rates in those with RAC.
The clinical utility of whole-body CT screening, with
analysis of RAC as part of a multibed analysis, is still
uncertain and these screenings cannot yet be recommended
as part of routine risk stratification. Whole-body CT scans
expose the individual to substantial radiation (24) and incur
the added risk of incidental findings requiring further
evaluation and invasive management. Our data suggest,
however, that determination of RAC may add to the
prognostic information contained in such scans above that
gleaned from analysis of standard Framingham risk factors
and of calcification in other vascular beds.
Study strengths and limitations. The strengths of our
study include a large sample size, the availability of calcifi-
cation in multiple vascular beds, and the long follow-up
time for mortality. We were able to adjust for standard
CVD risk factors as well as detailed measures of vascular
calcification in the coronary arteries as well as in other beds.
Limitations include the use of a self-referred cohort of
subjects rather than a community sample. These partici-
pants did not have estimated glomerular filtration rate or
proteinuria measured at the time of the whole-body scan,
and we therefore do not have renal function measures to
correlate with RAC. If estimated glomerular filtration rate or
proteinuria is a true confounder of the association between
RAC and mortality, however, one would have to postulate that
decreased kidney function leads to both RAC and mortality.
We do not know of supportive data for this hypothesis. RAC
might itself cause a decreased estimated glomerular filtration
rate, which is then a risk factor for mortality (mediation); we
cannot assess this by using the available data. History of CVD
and of CVD risk factors was by self-report and was not
confirmed via review of medical charts. We did not have
information about the ethnic background of the participants,
C-Statistics, IDI, and NRI for the Assessment of CAC and RACin Add tion to FRS in Predicting All-Cau e a d Cardiovascular MortTable 4 C-Statistics, IDI, and NRI for the Assessment of AC ain Addition to FRS in Predicting All-Cause and Cardiov
All-Cause Mortality
C-Statistic IDI
1. Base model alone (hard FRS) 0.69 (0.65–0.73) /
2. Base plus CAC 0.73 (0.694–0.77) 0.016 vs. #1
p values (vs. model 1) 0.001 0.0001
3. Base plus CAC plus RAC 0.77 (0.74–0.81) 0.036 vs. #1
0.020 vs. #2
p values (vs. model 1) 0.0001 0.0001
p values (vs. model 2) 0.0002 0.0001
FRS  Framingham risk score; IDI  integrated discrimination improvement; NRI  net reclassifinor do we have information about peripheral vascular disease,other comorbid diseases, or details of exercise habits. We
cannot exclude the possibility of residual confounding because
of these limits on the covariates available to us.
Conclusions
RAC was associated with all-cause mortality independent of
traditional cardiac risk factors. The association was attenu-
ated but was still present after adjustment for vascular
calcification in other locations and was minimally attenu-
ated by adjustment for hypertension. Adding RAC to a
predictive model of all-cause mortality using the Framing-
ham hard CHD score and the CAC score improved the
predictive value of the model. For cardiovascular mortality,
the findings were limited by the number of cardiovascular
deaths, and Cox proportional hazards models did not
demonstrate significance after multivariate adjustment.
Further work should examine whether similar associations are
seen in groups with a higher prevalence of diabetes and vascular
disease, because the findings may differ across populations, and
should investigate the associations of RAC with CVD events and
CVD mortality in these higher-risk populations.
Reprint requests and correspondence: Dr. Dena E. Rifkin,
University of California-San Diego, Mail code 9111H, Division of
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